Tramadol intravenous - Revogenex/Avenue Therapeutics

Drug Profile

Tramadol intravenous - Revogenex/Avenue Therapeutics

Alternative Names: AVE-901; IV tramadol - Revogenex/Avenue Therapeutics; RVX 109; Tramadol hydrochloride - Revogenex/Avenue Therapeutics

Latest Information Update: 25 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revogenex
  • Developer Avenue Therapeutics
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 22 May 2018 Efficacy, pharmacokinetics and adverse events data from a phase III trial in severe Postoperative pain following bunionectomy surgery released by Avenue Therapeutics
  • 03 May 2018 Avenue Therapeutics completed enrolment in a phase III trial for Postoperative pain in USA
  • 28 Mar 2018 Avenue Therapeutics receives Notice of Allowance for patents related to Intravenous tramadol, in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top